Cargando…
Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study
PURPOSE: Comparison of efficacy of propiverine extended release (ER) 30 mg o.d. in the treatment of male OAB administered as monotherapy (MT) or add-on to α-blockers (combination treatment, CT) in relation to maximum urinary flow (Q(max)) in a non-interventional study. METHODS: Men ≥40 years with OA...
Autores principales: | Oelke, Matthias, Murgas, Sandra, Baumann, Ina, Schnabel, Frieder, Michel, Martin C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062756/ https://www.ncbi.nlm.nih.gov/pubmed/21327673 http://dx.doi.org/10.1007/s00345-011-0654-7 |
Ejemplares similares
-
Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting
por: Amiri, Marjan, et al.
Publicado: (2021) -
What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine
por: Müderrisoglu, A. Elif, et al.
Publicado: (2022) -
Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany
por: Murgas, Sandra, et al.
Publicado: (2019) -
The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum
por: Wuest, Melinda, et al.
Publicado: (2011) -
Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH
por: Gravas, Stavros, et al.
Publicado: (2009)